Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

Abstract

The addition of 5mg/day of oral olanzapine to standard therapy can reduce the frequency of CINV and improve QOL of patients receiving highly or moderately emetogenic chemotherapy.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

“…19,20 These trials showed that when olanzapine was added to guidelinedirected prophylactic agents, nausea and emesis were significantly reduced. The efficacy of olanzapine for nausea control contrasts with the findings in clinical trials of NK 1 -receptor antagonists.…”

“…18 Additional single-institution phase 3 studies have shown that olanzapine combined with standard antiemetic agents improves control of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy. 19,20 A recent review, however, pointed to possible methodologic issues in these single-institution studies and called for well-planned, randomized, double-blind, multicenter studies to evaluate the role of olanzapine in the prevention of chemotherapy-induced nausea and vomiting. 21 The primary objective of the current trial was to evaluate olanzapine, as compared with placebo, for the control of nausea in patients receiving highly emetogenic chemotherapy, with nausea prevention assessed during three periods: 0 to 24 hours, 25 to 120 hours, and 0 to 120 hours after chemotherapy.…”

Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

“…Olanzapine improved the CR and nausea of the delayed period and overall period CINV and the quality of life in patients. In another trial, this one having a randomized, double-blind, placebo-controlled design, 20 44 patients scheduled to receive MEC or HEC received a 5-HT3 receptor antagonist, dexamethasone and a NK-1 receptor antagonist. Patients were then randomized to receive 5 mg of olanzapine daily or placebo for 6 days beginning on the day before chemotherapy or placebo.…”

Olanzapine Combined With Standard Antiemetic Regimens for Prevention of Chemotherapy Therapy-Induced Nausea and Vomiting: A Single-Center Experience From South India

“…Often, the cancer patients have some symptoms of depression and anxiety, and olanzapine can also exert an antidepressant effect in these patients [13,14]. Although there are studies [15][16][17][18][19][20] describing the use of olanzapine for prevention of CINV, there is scarcity of data on Indian patients. Hence, our study was undertaken to compare the effectiveness of olanzapine containing antiemetic regimens with standard regimensJames et al…”